{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-23-020094","form_type":"8-K","ticker":"PVLA","cik":"0001583648","company_name":"PALVELLA THERAPEUTICS, INC.","filed_at":"2023-07-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.431864+00:00","generated_at":"2026-06-13T07:02:01.506241+00:00","sec_items":["1.02","2.02","2.05","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Pieris terminates AstraZeneca deal, cuts 70% workforce, explores strategic alternatives","bullets":["AstraZeneca terminates R&D collaboration effective Oct 15, 2023 due to non-clinical safety findings in elarekibep toxicology study.","Workforce reduced by ~70%; expects ~$3.4M severance costs in Q3 2023.","Cash, equivalents, investments ~$54.9M as of June 30, 2023 (preliminary).","Pieris hires Stifel as financial advisor to explore strategic alternatives including M&A, licensing, or sale.","Focus shifted to advancing cinrebafusp alfa, PRS-220, PRS-400; no assurance of transaction outcome."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-23-020094","json":"https://secwatch.observer/filing/0001437749-23-020094.json","markdown":"https://secwatch.observer/filing/0001437749-23-020094.md","text":"https://secwatch.observer/filing/0001437749-23-020094.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583648/000143774923020094/0001437749-23-020094-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583648/000143774923020094/pirs20230705_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T07:02:01.506241+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a474e97947a04851793b1a7ead1b843edf2b49c6","claim":"PALVELLA THERAPEUTICS, INC. announced a restructuring with charges of approximately $3.4 million (approximately 70%).","evidence_excerpt":"on July 17, 2023, the Board of Directors of the Company approved a reduction in force of the Company's workforce by approximately 70% to be substantially completed in the fourth quarter of 2023 (the \"Workplace Reduction\"). As a result of the Workplace Reduction, the Company expects to incur estimated severance and other employee termination-related costs of approximately $3.4 million in the third quarter 2023.","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1583648/000143774923020094/0001437749-23-020094-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $3.4 million"},{"label":"Headcount","value":"approximately 70%"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}